In vitro studies show that inhibiting the MEK5/ERK5 pathway markedly diminishes the proliferative and colony-forming capacities of primary chronic myelogenous leukemia (CML) cells [93]. This evidence concerns the gene MAP2K5 and chronic myelogenous leukemia, BCR-ABL1 positive.